These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2233757)

  • 1. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Mol Immunol; 1990 Oct; 27(10):957-64. PubMed ID: 2233757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach.
    Juhl H; Sievers M; Baltzer K; Helmig F; Wolf H; Brenner W; Kalthoff H
    Cancer Res; 1995 Dec; 55(23 Suppl):5749s-5755s. PubMed ID: 7493340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
    Vogel CW; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7707-11. PubMed ID: 6950410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
    Cheung NK; Walter EI; Smith-Mensah WH; Ratnoff WD; Tykocinski ML; Medof ME
    J Clin Invest; 1988 Apr; 81(4):1122-8. PubMed ID: 2450893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation.
    Zara J; Pomato N; McCabe RP; Bredehorst R; Vogel CW
    Bioconjug Chem; 1995; 6(4):367-72. PubMed ID: 7578355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation.
    Müller B; Müller-Ruchholtz W
    Leuk Res; 1987; 11(5):461-8. PubMed ID: 3573809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody conjugates with cobra venom factor. Synthesis and biochemical characterization.
    Petrella EC; Wilkie SD; Smith CA; Morgan AC; Vogel CW
    J Immunol Methods; 1987 Nov; 104(1-2):159-72. PubMed ID: 3500233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective antitumor effect of thioether-linked immunotoxins composed of gelonin and monoclonal antibody to alpha-fetoprotein or its F(ab')2 fragment.
    Masuda K; Takahashi K; Hirano K; Takagishi Y
    Tumour Biol; 1994; 15(3):175-83. PubMed ID: 7521059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
    Cheung NK; Modak S
    Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
    Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
    Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes.
    Kushner BH; Cheung NK
    Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
    Brown EJ; Joiner KA; Frank MM
    J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
    Raso V; Ritz J; Basala M; Schlossman SF
    Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbohydrate-directed conjugation of cobra venom factor to antibody by selective derivatization of the terminal galactose residues.
    Fu Q; Gowda DC
    Bioconjug Chem; 2001; 12(2):271-9. PubMed ID: 11312689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
    Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
    Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.